Nancy joined RiverVest in 2016 and focuses on both biopharmaceutical and medical device opportunities. Currently, Nancy serves as a member of the Board of Directors at Scout Bio, Inc., Bluejay Therapeutics, Sequre Dx, and Biolinq, Inc. She formerly was a member of the Board of Directors at Xilio Therapeutics (NASDAQ: XLO).
Previously, Nancy was a principal with BioMed Ventures. Nancy started her career as a scientist at Phenomix, a venture-backed discovery biotech company in San Diego.
Trained in the areas of immunology and oncology, Nancy earned a B.S. with honors in Biology from the California Institute of Technology and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She conducted postdoctoral training at the University of California, San Francisco, as a fellow of the Leukemia & Lymphoma Society.